Evolent Health Q2 Earnings Review: Debt Is Distressing, But Business Is Booming
Evolent Health, Inc. is awarded a contrarian Buy rating despite extreme indebtedness and recent net losses. EVH trades at a deeply distressed valuation (~0.2x forward sales) due to ~$967m long-term debt and persistent GAAP losses. Management projects >25% revenue growth and adjusted EBITDA ≥$150m in 2027, aiming to improve leverage and capital structure.
Evolent Health Q2 Earnings Call Highlights
Evolent Health NYSE: EVH reported second-quarter revenue of $653 million, up 31% from the first quarter, and adjusted EBITDA of $28 million, up 27% sequentially, as the company benefited from the May launch of its Highmark partnership and continued growth in its Performance Suite business.
Evolent Health, Inc. (EVH) Q2 2026 Earnings Call Transcript
Evolent Health, Inc. (EVH) Q2 2026 Earnings Call Transcript
Compared to Estimates, Evolent Health (EVH) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Evolent Health (EVH) Tops Q2 Earnings and Revenue Estimates
Evolent Health (EVH) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to a loss of $0.1 per share a year ago.
Should You Buy Evolent Health (EVH) After Golden Cross?
Evolent Health, Inc (EVH) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, EVH's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Strength Seen in Evolent Health (EVH): Can Its 9.5% Jump Turn into More Strength?
Evolent Health (EVH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Evolent Health Q1 Earnings Call Highlights
Evolent Health NYSE: EVH reported first-quarter 2026 results that management said were in line with expectations, while reiterating its full-year outlook and highlighting new contract wins, early progress on major client launches and continued investment in automation.
Compared to Estimates, Evolent Health (EVH) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Evolent Health (EVH) Reports Q1 Loss, Misses Revenue Estimates
Evolent Health (EVH) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.06 per share a year ago.
8 Knots Management LLC Lowers Position in Evolent Health, Inc $EVH
8 Knots Management LLC trimmed its holdings in shares of Evolent Health, Inc (NYSE: EVH) by 39.3% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,768,113 shares of the technology company's stock after selling 1,145,022 shares during the
Evolent Health: Cheap, Levered, But Ready To Rebound
Evolent Health, Inc. is rated a Buy, with turnaround momentum and risk/reward now favoring upside after recent operational and strategic shifts. EVH's Performance Suite model now covers ~90% of revenue, offering risk protection and greater earnings predictability, despite near-term profit headwinds from new contract launches. Oncology drives EVH's growth, with strong customer retention (>98%) and cost discipline via AI automation and workforce efficiencies delivering $20M+ in annualized savings.
